Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.

ABSTRACT:

Objective

Prostate cancer remains a prevalent global health challenge, with limited treatment options for advanced stages. There is a critical need to identify effective therapies through systematic integration of genomic and biological data.

Methods

We analyzed 10,911 single nucleotide polymorphisms (SNPs) in 554 genes from genome- and phenome-wide association studies to identify biological risk genes for prostate cancer. Bioinformatic analysis was used to map these genes to key pathways and potential drug targets. Drug repurposing opportunities were assessed through Connectivity Map (CMap) transcriptomic signature analysis in the PC3 prostate cancer cell line, with additional molecular docking studies to evaluate drug-target interactions.

Results

We identified 77 pr

SUBMITTER: Irham LM 

PROVIDER: S-EPMC12326658 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature